• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session

    12/20/22 1:19:34 PM ET
    $ACST
    $AEI
    $AGFY
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate
    Finance
    Get the next $ACST alert in real time by email

    Gainers

    • IceCure Medical Ltd (NASDAQ:ICCM) shares jumped 296% to $3.71 after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who cannot be offered kidney-preserving surgery.
    • Avaya Holdings Corp. (NYSE:AVYA) gained 57% to $0.2384.
    • Athenex, Inc. (NASDAQ:ATNX) surged 47% to $0.1991 after the company announced Quantum Leap Healthcare Collaborative reported a trial result of I-SPY2 trial for oral paclitaxel in combination with PD-1 and carboplatin in neoadjuvant breast cancer.
    • Verona Pharma plc (NASDAQ:VRNA) shares climbed 40.5% to $18.71 after the company announced ensifentrine met primary and key secondary endpoints in the Phase 3 ENHANCE-1 trial for COPD.
    • Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) shares climbed 33.9% to $0.4194. Vallon Pharmaceuticals and GRI Bio recently announced they entered into a merger agreement.
    • Dragonfly Energy Holdings Corp. (NASDAQ:DFLI) surged 29.7% to $25.95.
    • IAMGOLD Corporation (NYSE:IAG) gained 26.9% to $2.31 after the company announced a transaction with Sumimoto Metal Mining to provide up to $340 million in additional funding to the contruction of the Côté Gold Project. Also, the company announced an agreement to sell its Boto Gold Project and surrounding exploration assets to Managem for a total consideration of $282 million.
    • United Insurance Holdings Corp. (NASDAQ:UIHC) gained 24.7% to $0.6256. United Insurance Holdings Chief Operating Officer Christopher Griffith bought a total of 20,000 shares at an average price of $0.57.
    • Acasti Pharma Inc. (NASDAQ:ACST) jumped 22.5% to $0.4899.
    • Alset Inc. (NASDAQ:AEI) jumped 22% to $0.1849.
    • Core Scientific, Inc. (NASDAQ:CORZ) gained 21.7% to $0.2463.
    • Baudax Bio, Inc. (NASDAQ:BXRX) rose 20.7% to $2.22. Baudax Bio recently announced initiation of a Phase II clinical trial evaluationg BX1000 in patients undergoing surgery.
    • Smart for Life, Inc. (NASDAQ:SMFL) rose 20.5% to $0.2415 after dropping 22% on Monday.
    • Exicure, Inc. (NASDAQ:XCUR) shares gained 18.9% to $0.88. Exicure 10% owner CBI USA, Inc. acquired a total of 3,400,000 shares at an average price of $1.60.
    • Appreciate Holdings, Inc. (NASDAQ:SFR) gained 18.4% to $1.48.
    • MediaAlpha, Inc. (NYSE:MAX) gained 17.5% to $18.71. JP Morgan upgraded MediaAlpha from Neutral to Overweight and raised the price target from $12 to $14.
    • Pagaya Technologies Ltd. (NASDAQ:PGY) rose 17.2% to $0.6705.
    • EverQuote, Inc. (NASDAQ:EVER) shares climbed 15.4% to $18.71 after JPMorgan upgraded the stock from Underweight to Overweight and raised its price target from $8 to $15.
    • Hycroft Mining Holding Corporation (NASDAQ:HYMC) gained 15.2% to $0.5245.
    • Taseko Mines Limited (NYSE:TGB) gained 14.8% to $1.4358 after the company announced it formed a strategic partnershi with Mitsui to develop the company's Florence Copper project.
    • Surrozen, Inc. (NASDAQ:SRZN) rose 14.5% to $0.55 after gaining 8% on Monday.
    • Mitsubishi UFJ Financial Group, Inc. (NYSE:MUFG) rose 14.3% to $6.34.
    • Landos Biopharma, Inc. (NASDAQ:LABP) gained 14.3% to $0.4710.
    • DLocal Limited (NASDAQ:DLO) gained 14% to $15.03 after the company refuted a short-seller report and announced a share buyback program and proposed share purchases by key share holders.
    • Metacrine, Inc. (NASDAQ:MTCR) rose 13.6% to $0.3980. Tang Capital Partners reported in 13G filing a 7.1% stake in Metacrine.
    • Natura &Co Holding S.A. (NYSE:NTCO) gained 12.6% to $4.37.
    • Sumitomo Mitsui Financial Group, Inc. (NYSE:SMFG) rose 12.2% to $7.70.
    • Gol Linhas Aéreas Inteligentes S.A. (NYSE:GOL) gained 11.7% to $2.68.
    • Steelcase Inc. (NYSE:SCS) gained 11.6% to $6.98 after the company announced better-than-expected Q3 EPS results.
    • New Pacific Metals Corp. (NYSE:NEWP) jumped 11.4% to $2.4350.
    • Vivos Therapeutics, Inc. (NASDAQ:VVOS) gained 11.3% to $0.5475.
    • TAL Education Group (NYSE:TAL) rose 11.3% to $9.02.
    • Coeur Mining, Inc. (NYSE:CDE) gained 8.7% to $3.41.


    Losers

    • Caravelle International Group (NASDAQ:CACO) shares dipped 57.9% to $2.03 after declining over 12% on Monday.
    • Magenta Therapeutics, Inc. (NASDAQ:MGTA) dropped 44% to $0.4650 after the company reported it stopped dosing participants at the Cohort 4 dosing level and plans to dose additional participants at the Cohort 3 dosing level due to dose-limiting toxicities.
    • Entrada Therapeutics Inc (NASDAQ:TRDA) fell 33.5% to $13.22 after the company said it received a clinical hold notice from the FDA regarding its Investigational New Drug Application for ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy.
    • Axcella Health Inc. (NASDAQ:AXLA) shares fell 29.1% to $0.3048 after gaining 165% on Monday. Axcella Health recently announced organizational and program updates, including a reprioritization of its programs for Long COVID Fatigue and Nonalcoholic Steatohepatitis (NASH) and a restructuring of operations.
    • Arcus Biosciences, Inc. (NYSE:RCUS) fell 28.1% to $21.92. Gilead Sciences and Arcus Biosciences announced results from the fourth interim analysis of the ARC-7 Phase 2 study for metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase mutations.
    • BioVie Inc. (NASDAQ:BIVI) fell 27% to $7.27.
    • Soleno Therapeutics, Inc. (NASDAQ:SLNO) shares fell 26.3% to $1.3599. Soleno Therapeutics shares jumped around 104% on Monday after the company announced a financing commitment for up to $60 million..
    • AppTech Payments Corp. (NASDAQ:APCX) fell 24.4% to $1.0583 after jumping 55% on Monday.
    • Kineta Inc (NASDAQ:KA) fell 24.4% to $3.76.
    • Cosmos Health Inc. (NASDAQ:COSM) dropped 22% to $5.91. Cosmos Health recently announced pricing of a $32.5 million registered direct offering and concurrent private placement priced at-the-market.
    • Prenetics Global Limited (NASDAQ:PRE) fell 20.4% to $1.91.
    • Camber Energy, Inc. (NYSE:CEI) fell 20% to $0.0857. Camber Energy shares jumped 73% on Monday after the company announced an anticipated effective date of December 21, 2022 for its previously-announced 1-for-50 reverse stock split.
    • Crown ElectroKinetics Corp. (NASDAQ:CRKN) fell 18.2% to $0.1451 after dropping 13% on Monday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
    • Agrify Corporation (NASDAQ:AGFY) dropped 17.8% to $0.2750.
    • NantHealth, Inc. (NASDAQ:NH) shares fell 17.4% to $3.4801 after dropping 26% on Monday. NantHealth recently announced a 1-for-15 reverse stock split.
    • WaveDancer, Inc. (NASDAQ:WAVD) dipped 15.7% to $0.3975.
    • Duos Technologies Group, Inc. (NASDAQ:DUOT) dropped 14.9% to $2.05.
    • Embecta Corp. (NASDAQ:EMBC) fell 14.8% to $27.65 after the company reported a decline in Q4 sales.
    • Vigil Neuroscience, Inc. (NASDAQ:VIGL) dropped 14.5% to $10.51.
    • MicroAlgo Inc. (NASDAQ:MLGO) declined 14.3% to $1.44.
    • Mullen Automotive, Inc. (NASDAQ:MULN) fell 14.1% to $0.2330.
    • Leju Holdings Limited (NYSE:LEJU) dropped 13.5% to $1.35.
    • Allarity Therapeutics, Inc. (NASDAQ:ALLR) fell 13.4% to $0.3031.
    • Ark Restaurants Corp. (NASDAQ:ARKR) dropped 13.1% to $15.74 after the company reported a sharp decline in quarterly earnings.
    • Embecta Corp. (NASDAQ:EMBC) fell 12.4% to $28.47 after the company reported Q4 earnings results.
    • ioneer Ltd (NASDAQ:IONR) dropped 12.3% to $11.96.
    • Reed's, Inc. (NASDAQ:REED) fell 12% to $0.0889 after gaining around 35% on Monday.
    • Otonomy, Inc (NASDAQ:OTIC) fell 9.6% to $0.1037. Otonomy's board of directors has approved and adopted a Plan of Liquidation and Dissolution that would include the distribution of remaining cash to stockholders following an orderly wind-down of the company's operations, including the proceeds from the sale of any pipeline assets.
    • Hoth Therapeutics, Inc. (NASDAQ:HOTH) fell 9.5% to $2.68 after dropping 14% on Monday. Hoth Therapeutics recently announced submission of investigational new drug application for HT-001.
    • HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) shares fell 8.7% to $0.7518 after jumping 49% on Monday.
    • Sintx Technologies, Inc. (NASDAQ:SINT) dropped 7% to $7.25. Sintx Technologies announced a 1-for-100 reverse stock split, effective December 20, 2022.

    Also check this out Ethereum Tops $1,200; Chain Becomes Top Loser.

    Get the next $ACST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACST
    $AEI
    $AGFY
    $ALLR

    CompanyDatePrice TargetRatingAnalyst
    Entrada Therapeutics Inc.
    $TRDA
    4/1/2026Overweight
    Cantor Fitzgerald
    Coeur Mining Inc.
    $CDE
    3/25/2026$27.00Outperform
    BMO Capital Markets
    Prenetics Global Limited
    $PRE
    3/16/2026$29.00Buy
    Lake Street
    Core Scientific Inc.
    $CORZ
    3/3/2026$23.00Hold → Buy
    Needham
    Coeur Mining Inc.
    $CDE
    2/20/2026Buy → Hold
    Canaccord Genuity
    Surrozen Inc.
    $SRZN
    2/19/2026$40.00Overweight
    Cantor Fitzgerald
    Arcus Biosciences Inc.
    $RCUS
    2/12/2026$23.00Overweight → Equal Weight
    Wells Fargo
    Prenetics Global Limited
    $PRE
    2/11/2026$36.00Buy
    Roth Capital
    More analyst ratings

    $ACST
    $AEI
    $AGFY
    $ALLR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

    NEW YORK, April 2, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today announced the closing of its previously announced registered direct offering for the purchase and sale of an aggregate of 2,857,144 shares of its common stock (or common stock equivalents in lieu thereof) at an offering price of $0.70 per share of common stock (or per common stock equivalent in lieu thereof). Additionally, in a concurrent private placement, the Company issued and sold unregistered warrants to purchase up to an aggregate of 2,857,144 shares of common stock at an exercise price of $0.

    4/2/26 4:05:00 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MediaAlpha Launches the Insurance Industry's First Carrier-Approved Conversational AI Application for Carriers and Consumers

    LOS ANGELES, April 02, 2026 (GLOBE NEWSWIRE) -- MediaAlpha, Inc. (NYSE:MAX), the leading customer acquisition infrastructure for insurance carriers, today announced the launch of the first carrier-approved conversational AI application powered by ChatGPT technology for auto insurance shopping. Built on MediaAlpha's trusted programmatic marketplace, the app modernizes how consumers find and connect with auto insurance carriers, while meeting the compliance, accuracy, and brand standards that carriers require. "Conversational AI is changing how consumers research and shop for insurance, and our industry has a responsibility to get this right," said Steve Yi, MediaAlpha Co-Founder and CEO. "

    4/2/26 9:00:00 AM ET
    $MAX
    Real Estate

    Prenetics Announces NBA Champion and Two-Time MVP Giannis Antetokounmpo as IM8 Global Partner and Shareholder in Multi-Year Partnership

    Giannis becomes the first NBA athlete shareholder in a NASDAQ-listed health and longevity brand, joining the fastest supplement company ever to reach $100M ARR in just 11 months Giannis unlocks 35 million followers across social channels - NBA broadcasted in 215 countries To learn more about Giannis and IM8, please visit www.im8health.com NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today announced a multi-year global partnership with NBA Champion and two-time MVP Giannis Antetokounmpo. Giannis becomes a Global Partner of

    4/2/26 9:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    $ACST
    $AEI
    $AGFY
    $ALLR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sullivan Adam Taylor

    4 - Core Scientific, Inc./tx (0001839341) (Issuer)

    4/2/26 8:26:21 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Duchene Todd M

    4 - Core Scientific, Inc./tx (0001839341) (Issuer)

    4/2/26 8:25:54 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Skaff Michael C

    4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

    4/2/26 7:34:11 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $ACST
    $AEI
    $AGFY
    $ALLR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Entrada Therapeutics

    Cantor Fitzgerald initiated coverage of Entrada Therapeutics with a rating of Overweight

    4/1/26 8:36:28 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BMO Capital Markets resumed coverage on Coeur Mining with a new price target

    BMO Capital Markets resumed coverage of Coeur Mining with a rating of Outperform and set a new price target of $27.00

    3/25/26 8:52:52 AM ET
    $CDE
    Precious Metals
    Basic Materials

    Lake Street initiated coverage on Prenetics Group Ltd. with a new price target

    Lake Street initiated coverage of Prenetics Group Ltd. with a rating of Buy and set a new price target of $29.00

    3/16/26 8:45:09 AM ET
    $PRE
    Blank Checks
    Finance

    $ACST
    $AEI
    $AGFY
    $ALLR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tcg Crossover Gp Ii, Llc bought $1,220,362 worth of shares (48,997 units at $24.91) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    3/16/26 7:05:51 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Weiss Eric Stanton bought $101,700 worth of shares (7,000 units at $14.53), increasing direct ownership by 3% to 252,262 units (SEC Form 4)

    4 - Core Scientific, Inc./tx (0001839341) (Issuer)

    3/10/26 4:08:53 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ACST
    $AEI
    $AGFY
    $ALLR
    SEC Filings

    View All

    Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

    4/3/26 4:05:33 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Duos Technologies Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - DUOS TECHNOLOGIES GROUP, INC. (0001396536) (Filer)

    4/2/26 5:29:36 PM ET
    $DUOT
    Computer Software: Prepackaged Software
    Technology

    Hoth Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

    4/2/26 4:18:12 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACST
    $AEI
    $AGFY
    $ALLR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for FAMOTIDINE issued to ATHENEX INC

    Submission status for ATHENEX INC's drug FAMOTIDINE (SUPPL-13) with active ingredient FAMOTIDINE has changed to 'Approval' on 01/07/2022. Application Category: ANDA, Application Number: 075684, Application Classification: Labeling

    1/12/22 4:41:30 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for KLISYRI

    Submission status for ATHENEX INC's drug KLISYRI (ORIG-1) with active ingredient TIRBANIBULIN has changed to 'Approval' on 12/14/2020. Application Category: NDA, Application Number: 213189, Application Classification: Type 1 - New Molecular Entity

    12/20/20 4:30:55 PM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACST
    $AEI
    $AGFY
    $ALLR
    Financials

    Live finance-specific insights

    View All

    Duos Technologies Reports Record 2025 Results, Driving Momentum in AI and Edge Infrastructure

    JACKSONVILLE, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Duos Technologies Group, Inc. ("Duos" or the "Company") (NASDAQ:DUOT), a provider of modular, colocation Edge and AI data centers and technology infrastructure solutions, reported financial results for the fourth quarter ("Q4 2025") and the year ended December 31, 2025. The Company delivered record annual revenue and marked a pivotal year of transformation, driven by rapid expansion of its Edge Data Center platform, entry into high-density AI infrastructure, and the launch of GPU-as-a-Service ("GPUaaS") and Technology Solutions. Supported by significant capital raises and accelerating customer demand, Duos enters 2026 with strong momen

    3/31/26 4:28:05 PM ET
    $DUOT
    Computer Software: Prepackaged Software
    Technology

    dLocal to Report First Quarter 2026 Financial Results

    MONTEVIDEO, Uruguay, March 31, 2026 (GLOBE NEWSWIRE) -- DLocal Limited (NASDAQ:DLO, "dLocal" or the "Company")), a leading financial technology company powering payments across emerging markets, intends to release financial results for its first fiscal quarter ended March 31, 2026 on May 14, 2026 after market close. The Company will host a conference call and video webcast on May 14, 2026 at 6:00 p.m. Eastern Time. Please click here to pre-register for the conference call and obtain your dial in number and passcode. The live conference call can be also accessed via audio webcast at the investor relations section of the Company's website, at https://investor.dlocal.com/. An archive of the

    3/31/26 4:10:02 PM ET
    $DLO
    Real Estate

    Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

         Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for stenoparib, enabling accelerated development in advanced ovarian cancerDurable clinical benefit observed in ongoing stenoparib ovarian cancer study, including patients treated for nearly 30 months, with new Phase 2 protocol implementedExpansion of stenoparib development beyond ovarian cancer with the launch of a VA-funded Phase 2 combination study in recurrent small cell lung cancer TARPON SPRINGS, Fla., March 31, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2

    3/31/26 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACST
    $AEI
    $AGFY
    $ALLR
    Leadership Updates

    Live Leadership Updates

    View All

    IceCure Appoints Meir Peleg as Chief Financial Officer

    Meir Peleg brings over 20 years of financial leadership and experience including with Nasdaq listed companiesIceCure intends to appoint Dr. Richard Fine as Medical Director CAESAREA, Israel, March 24, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the appointment of Mr. Meir Peleg as its Chief Financial Officer ("CFO"), effective May 17, 2026. The appointment comes as IceCure is

    3/24/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

    Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026 SALT LAKE CITY, Utah, March 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today provided a corporate business update highlighting recent clinical, operational, and leadership milestones that the Company believes position it for commercial expansion and future revenue growth. The update follows a series of key developments, including the successful completion of the first human surgical procedure us

    3/23/26 9:15:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions

    Continues to deliver record revenue and improving operating metricsSignificant expansion in the United States underway, with NOOR and other Sky Premium Life products expected to drive strong profitability supported by gross margins of approximately 75%NOOR Collagen alone is projected to generate more than $12 million in annualized revenue Strong growth expected ahead, driven by organic progress and M&A pipeline including a recent LOI to acquire an $11.5 million pharmacy distribution network Holds valuable non-core strategic real estate and digital assets with an estimated fair market value exceeding $18 million, providing meaningful balance sheet flexibilityEvaluating potential monetization

    3/19/26 12:45:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $ACST
    $AEI
    $AGFY
    $ALLR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Arcus Biosciences Inc.

    SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

    12/17/24 9:52:58 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Reeds Inc.

    SC 13D/A - REED'S, INC. (0001140215) (Subject)

    12/6/24 4:30:32 PM ET
    $REED

    Amendment: SEC Form SC 13D/A filed by Reeds Inc.

    SC 13D/A - REED'S, INC. (0001140215) (Subject)

    12/4/24 6:11:30 AM ET
    $REED